Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Cara licenses Enteris' Peptelligence to develop oral formulation of Korsuva

Executive Summary

Enteris BioPharma Inc. granted Cara Therapeutics Inc. a non-exclusive worldwide license (excluding Japan and South Korea) to its Peptelligence drug delivery technology to use in the development, manufacture, and commercialization of Cara's oral Korsuva (difelikefalin; CR845), a long-acting synthetic peptide peripheral kappa opioid receptor (KOR) agonist.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register